Filtered By:
Condition: Bleeding
Education: Study

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 7778 results found since Jan 2013.

Incidence of Arterial Thrombotic and Bleeding Events in Patients Who Develop Cancer After ST-elevation Myocardial Infarction
Conclusion Cancers increase unpredictable bleeding but not arterial thrombotic events in patients after STEMI.PMID:37612081 | DOI:10.2169/internalmedicine.2385-23
Source: Internal Medicine - August 23, 2023 Category: Internal Medicine Authors: Toshiharu Fujii Yuji Ikari Source Type: research

Cardiovascular and renal outcomes in patients with atrial fibrillation and stage 4 –5 chronic kidney disease receiving direct oral anticoagulants: a multicenter retrospective cohort study
AbstractThe role of direct oral anticoagulants (DOAC) in patients with atrial fibrillation (AF) and stage 4 –5 chronic kidney disease (CKD) is controversial. Electronic medical records from 2012 to 2021 were retrieved for patients with AF and stage 4–5 CKD receiving oral anticoagulants. Patients were separated into those receiving DOACs (dabigatran, rivaroxaban, apixaban, or edoxaban) or vitamin K ant agonists (VKA). Primary outcomes included ischemic stroke (IS), systemic thrombosis (SE), major bleeding, gastrointestinal bleeding, hemorrhagic stroke, acute myocardial infarction, cardiovascular death, and all-cause dea...
Source: Journal of Thrombosis and Thrombolysis - August 21, 2023 Category: Hematology Source Type: research

Screening over 100 000 patients in 39 general practices in the Netherlands for anticoagulation underprescription in atrial fibrillation: a descriptive, cross-sectional study
Conclusions In this large Dutch study among GPs, we observed 9.8% underprescription of OAC in AF patients. In 76% of the AF patients lacking a prescription for OAC, no documentation for deviating from the guidelines was found. Only in a minority of cases detection of OAC underprescription lead to OAC initiation.
Source: BMJ Open - August 18, 2023 Category: General Medicine Authors: Voorhout, L., Pisters, R., Geurts, C. H. P. H., Oostindjer, A., van Doorn, S., Rila, H., Fuijkschot, W. W., Verheugt, F., Hemels, M. E. W. Tags: Open access, Cardiovascular medicine Source Type: research

Natural history, angiographic presentation and outcomes of anterior cranial fossa dural arteriovenous fistulas
Conclusion Most ACF-dAVFs have a symptomatic presentation. Drainage through cortical veins is a key angiographic feature of ACF-dAVFs that accounts for their malignant course. Microsurgery is the most effective treatment. Due to the high risk of bleeding, closure of ACF-dAVFs is indicated regardless of presentation.
Source: Journal of NeuroInterventional Surgery - August 17, 2023 Category: Neurosurgery Authors: Sanchez, S., Raghuram, A., Wendt, L., Hayakawa, M., Chen, C.-J., Sheehan, J. P., Kim, L. J., Abecassis, I. J., Levitt, M. R., Meyer, R. M., Guniganti, R., Kansagra, A. P., Lanzino, G., Giordan, E., Brinjikji, W., Bulters, D. O., Durnford, A., Fox, W. C., Tags: Hemorrhagic stroke Source Type: research

Comparative outcomes associated with rivaroxaban versus warfarin use in elderly patients with atrial fibrillation or acute venous thromboembolism managed in the United States: a systematic review of observational studies
CONCLUSIONS: This systematic review supports findings from subgroup analyses of randomized controlled trials that, compared with warfarin, rivaroxaban is associated with generally neutral or positive effects on thrombosis and a mixed picture on bleeding outcomes in older adults with either NVAF or VTE treated in the United States.PMID:37584187 | DOI:10.1080/03007995.2023.2247988
Source: Current Medical Research and Opinion - August 16, 2023 Category: Research Authors: William L Baker Matthew S Roberts Youssef Bessada Kimberly S Caroti Veronica Ashton Brahim K Bookhart Craig I Coleman Source Type: research

Pharmacological interventions for asymptomatic carotid stenosis
CONCLUSIONS: Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality. High-quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis. In the interim, clinicians will have to use other sources of information.PMID:37565307 | PMC:PMC10401652 | DOI:10.1002/14651858.CD013573.pub2
Source: Atherosclerosis - August 11, 2023 Category: Cardiology Authors: Caroline Nb Clezar Carolina Dq Flumignan Nicolle Cassola Luis Cu Nakano Virginia Fm Trevisani Ronald Lg Flumignan Source Type: research

Cardiovascular effects of rivaroxaban in heart failure patients with sinus rhythm and coronary disease with and without diabetes: a retrospective international cohort study from COMMANDER-HF
Conclusions In COMMANDER-HF a diagnosis of diabetes conferred higher rates of cardiovascular events that, with exception of ischaemic stroke, was not substantially reduced by rivaroxaban. Rivaroxaban was associated with reduced risk of ischaemic stroke for patients with and without diabetes. Trial registration number NCT01877915; Post-results.
Source: BMJ Open - August 11, 2023 Category: General Medicine Authors: Sharma, A., Caldeira, D., Razaghizad, A., Pinto, F. J., van Veldhuisen, D. J., Mehra, M. R., Lam, C. S. P., Cleland, J., Anker, S. D., Greenberg, B., Ferreira, J. P., Zannad, F. Tags: Open access, Cardiovascular medicine Source Type: research

Ticagrelor versus clopidogrel after intracranial stent angioplasty: a real-world study
ConclusionIn our study involving patients with acute ischemic stroke who had undergone intracranial stenting, aspirin-ticagrelor was not found to be superior to aspirin-clopidogrel in reducing the rate of ischemic vascular events. The risk of bleeding did not differ between the two groups. Aspirin-ticagrelor does not lower total restenosis and symptomatic restenosis risk at follow-up.
Source: Frontiers in Neurology - August 11, 2023 Category: Neurology Source Type: research

Preferred monotherapy after short-term dual antiplatelet therapy: Systematic review and network Meta-analysis of randomized trials
CONCLUSIONS: Compared with aspirin monotherapy following short-term DAPT, ticagrelor following 3-month DAPT was associated with a reduced risk of primary bleeding outcomes without increasing any ischemic outcomes.PMID:37562542 | DOI:10.1016/j.jjcc.2023.08.001
Source: Journal of Cardiology - August 10, 2023 Category: Cardiology Authors: Satoshi Shoji Toshiki Kuno Hiroki Ueyama Hisato Takagi Alexandros Briasoulis Hyo-Soo Kim Bon-Kwon Koo Jeehoon Kang Hirotoshi Watanabe Takeshi Kimura Shun Kohsaka Source Type: research